Condition
Multisystem Inflammatory Syndrome in Children (MIS-C)
Total Trials
5
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed2
Recruiting1
Active Not Recruiting1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05287412Active Not RecruitingPrimary
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
NCT07126028Enrolling By InvitationPrimary
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
NCT04278404Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04640038Phase 3Completed
Contrast Enhanced Ultrasound in COVID-19
NCT04588363Completed
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Showing all 5 trials